Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

about

General Biomarker Recommendations for Lymphoma.Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care.

P2860

Q47593563-87133E5A-24E7-4666-9351-3D74CDA83DC0 Q52569157-E796914C-DFF0-489A-96DB-E54160A68327 Q52722711-1EA0279F-3D64-4910-BCEE-A02E5D4AFDFE

P2860

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Item

http://www.wikidata.org/entity/Q38775871

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

@en

type

Item

label

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

@en

prefLabel

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

@en

P1476

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

@en

P2093

Anas Younes

http://www.w3.org/2001/XMLSchema#string

Brad S Kahl

http://www.w3.org/2001/XMLSchema#string

Daniel O Persky

http://www.w3.org/2001/XMLSchema#string

John P Leonard

http://www.w3.org/2001/XMLSchema#string

Jonathan W Friedberg

http://www.w3.org/2001/XMLSchema#string

Joseph M Connors

http://www.w3.org/2001/XMLSchema#string

Kara M Kelly

http://www.w3.org/2001/XMLSchema#string

Lale Kostakaglu

http://www.w3.org/2001/XMLSchema#string

Lawrence Baizer

http://www.w3.org/2001/XMLSchema#string

Richard F Little

http://www.w3.org/2001/XMLSchema#string

P2860

Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma

Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

P31

scholarly article

P356

10.1093/JNCI/DJW249

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Andrew M Evens

Catherine S.M. Diefenbach

Nancy L Bartlett

P577

2016-12-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28040700

http://www.w3.org/2001/XMLSchema#string

P932

6059238

http://www.w3.org/2001/XMLSchema#string

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

about

P2860

P2860

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P932